KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Other Non-Current Assets (2016 - 2025)

Inovio Pharmaceuticals' Other Non-Current Assets history spans 16 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 255.3% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, up 255.3%, while the annual FY2024 figure was $2.0 million, 227.05% up from the prior year.
  • Other Non-Current Assets for Q3 2025 was $2.0 million at Inovio Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $25.9 million in Q1 2021 and bottomed at $566415.0 in Q3 2024.
  • The 5-year median for Other Non-Current Assets is $770144.0 (2022), against an average of $2.5 million.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 943.59% in 2021 before it tumbled 95.08% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.4 million in 2021, then plummeted by 52.02% to $684044.0 in 2022, then fell by 11.51% to $605315.0 in 2023, then surged by 227.05% to $2.0 million in 2024, then rose by 1.66% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Other Non-Current Assets are $2.0 million (Q3 2025), $2.0 million (Q2 2025), and $2.0 million (Q1 2025).